Expedited Scheduling Places New Sleep Aid in Schedule IV
April 21, 2020 at 00:23:42 ET
The newly approved sleep aid Dayvigo™ (lemborexant, Eisai Inc.) has been listed in Schedule IV under the expedited scheduling procedures of the Improving Regulatory Transparency for New Medical Therapies Act, Pub. L. No. 114-89 (2015) (85 Fed. Reg. 19387, Apr. 7, 2020).
On Dec. 20, 2019, the FDA approved lemborexant for the treatment of adult patients with insomnia characterized by... Read More
